sterias Biotherapeutics,
Inc. (NYSE MKT: AST) (the "Company"), a leading biotechnology company in the
emerging field of regenerative medicine, today announced that it has
commenced an underwritten public offering of its common stock. MLV & Co.
LLC is acting as the Sole Book-Running Manager for the offering.
The offering will be made pursuant to the Company's existing effective shelf
registration statement, previously filed with the Securities and Exchange
Commission. This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities nor will there be any sale of
these securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction.
The offering of these securities will be made only by means of a prospectus
and related prospectus supplement, when available. Before you invest, you
should read the prospectus in the registration statement and related
prospectus supplements and other documents that the Company has filed with
the SEC for more complete information about the Company and this offering.
Copies of the prospectus and accompanying preliminary prospectus supplement
relating to these securities may be obtained for free by visiting EDGAR on
the SEC website at www.sec.gov or by written request to Asterias
Biotherapeutics, Inc., 230 Constitution Drive, Menlo Park, CA 94025.
Alternatively, copies of the prospectus and accompanying preliminary
prospectus supplement relating to these securities may be obtained by
contacting MLV & Co. LLC, 1251 Avenue of the Americas, New York, NY 10020,
Attention: Randy Billhardt, Email: rbillhardt@mlvco.com; Telephone: (888)
344-2272.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in